Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Zuclopenthixol
Drug ID BADD_D02398
Description Zuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent. Zuclopenthixol is a thioxanthene-based neuroleptic with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. Major brands of zuclopenthixol are Cisordinol, Acuphase, and Clopixol. This drug is a liquid. This compound belongs to the thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom. Known drug targets of zuclopenthixol include 5-hydroxytryptamine receptor 2A, D(1B) dopamine receptor, D(2) dopamine receptor, D(1A) dopamine receptor, and alpha-1A adrenergic receptor. It is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States.
Indications and Usage Used in the management of acute psychoses such as mania or schizophrenia. However, the use of zuclopenthixol acetate in psychiatric emergencies as an alternative to standard treatments (haloperidol, clotiapine, etc.) should be cautioned, since well executed and documented trials of zuclopenthixol acetate for this use have yet to be conducted. Zuclopenthixol acetate is not intended for long-term use.
Marketing Status Not Available
ATC Code N05AF05
DrugBank ID DB01624
KEGG ID D03556
MeSH ID D003006
PubChem ID 5311507
NDC Product Code Not Available
Synonyms Clopenthixol | Zuclopenthixol | alpha-Clopenthixol | alpha Clopenthixol | Cisordinol
Chemical Information
Molecular Formula C22H25ClN2OS
CAS Registry Number 53772-83-1
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Tardive dyskinesiaD(2) dopamine receptorP14416T6716210821369; 10379516; 10893495; 9777180; 10889553
Tardive dyskinesiaD(3) dopamine receptorP35462T0255110821369; 10379516; 10893495; 9777180; 10889553
Tardive dyskinesiaD(4) dopamine receptorP21917T2498310821369; 10379516; 10893495; 9777180; 10889553
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abnormal dreams19.02.03.001; Available
Accommodation disorder06.02.04.001--Not Available
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Anaphylactic shock24.06.02.004; Available
Apathy19.04.04.002--Not Available
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.001--Not Available
Blood bilirubin increased13.03.01.008--
Body temperature decreased13.15.01.010--Not Available
Body temperature increased13.15.01.001--Not Available
Breast enlargement21.05.04.001--Not Available
Dermatitis23.03.04.002--Not Available
Discomfort08.01.08.003--Not Available
Disturbance in attention19.21.02.002;
Dizziness postural17.02.05.004;; Available
Drug withdrawal syndrome19.07.02.011; Available
Drug withdrawal syndrome neonatal19.07.02.012;; Available
Dry mouth07.06.01.002--
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages